CoreWeave CEO Says the Firm Doesn’t Need Core Scientific if Acquisition Offer Is Rejected

CoreWeave CEO Michael Intrator stated that while acquiring Core Scientific would be beneficial, it is not essential for the AI infrastructure firm's strategic plans, despite an outstanding $9 billion all-stock offer. The bid has faced significant criticism for undervaluing Core Scientific from proxy advisor ISS and major shareholder Two Seas Capital, yet Intrator confirmed CoreWeave will not raise its offer, deeming the current price final and fair ahead of the October 30 shareholder vote. Concurrently, CoreWeave is actively expanding through other strategic acquisitions.

Analysis

CoreWeave (CRWV) CEO Michael Intrator confirmed the $9 billion all-stock offer for Core Scientific (CORZ) is final and will not be raised, despite significant shareholder and proxy advisor opposition. The July offer prompted an 18% decline in CORZ stock and drew criticism from ISS and major shareholder Two Seas Capital for undervaluation. Intrator, however, asserts the bid fairly represents the "relative value" of the companies.

This unwavering position, ahead of the October 30 shareholder vote, highlights CoreWeave's conviction in its valuation and a disinclination to increase the offer. The "mildly negative" general sentiment and "negative" per-ticker sentiment for CORZ (-0.7) underscore market concerns regarding the offer's adequacy for Core Scientific shareholders. Conversely, CoreWeave maintains a "positive" per-ticker sentiment (0.7), suggesting market confidence in its overall strategy.

CoreWeave is simultaneously advancing its strategic expansion through other acquisitions, including OpenPipe, Weights & Biases, and Monolith, indicating a diversified growth path. Wall Street analysts hold a "Moderate Buy" consensus on CRWV, with an average price target of $157.63 implying a 26.6% upside, reinforcing a favorable outlook for CoreWeave's independent trajectory.

Key Decisions for Investors

• Core Scientific (CORZ) shareholders should critically evaluate the implications of CoreWeave's final offer and the upcoming October 30 vote, weighing the current acquisition terms against potential standalone value or alternative bids.
• Investors in CoreWeave (CRWV) should monitor the outcome of the Core Scientific vote for short-term market volatility, while considering the company's broader strategic expansion and positive analyst outlook as key long-term drivers.
• Assess CoreWeave's diversified acquisition strategy in AI infrastructure, which appears robust and less dependent on the Core Scientific deal's success, as a significant factor for future growth.